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As dengue vaccines enter clinical trials, there is a need for rapid and quantitative assays to measure
neutralization. We have developed flow-based neutralization assays which generated results similar to those
generated by the established, plaque reduction neutralization test. The flow assays are an improvement, as they
use human cells and allow for high-throughput screening.
Dengue viruses (DENVs) are members of the family Flaviviri-
dae and consist of four serotypes, designated DENV serotype 1
(DENV1) through DENV4 (6, 11). Although there is extensive
cross-reactivity among DENVs in serological tests, there is only
limited cross-protective immunity in humans, and a person can
have multiple infections with different serotypes during his or her
life (19). People exposed to secondary DENV infections face a
greater risk of severe disease, indicating that preexisting cross-
reactive immunity can exacerbate disease (5, 8).
Given the evidence that immunity to DENV can lead to
more severe disease, an effective dengue vaccine must provide
balanced, long-term protection against all four serotypes. To
evaluate the safety and efficacy of vaccines, we need precise
and easy-to-use assays that measure DENV neutralization.
The current “gold standard” for measuring neutralization is
the plaque reduction neutralization test (PRNT) (17). PRNT is
time-consuming and uses nonhuman cell lines. Some strains of
DENV, especially clinical isolates, do not form plaques and
cannot be used in PRNT. PRNT is also not suitable for high-
throughput screening of large collections of serum specimens.
Flow cytometry has been used to detect DENV in clinical
samples and to measure the ability of the virus to infect a
variety of cells (1, 13). More recently, a flow cytometry-based
DENV titration assay was introduced (9). Flow cytometry-
based assays have also been used to measure antibody-medi-
ated neutralization and enhancement of DENV (4, 10, 14). In
this study we report on the development of 96-well-format,
flow cytometry-based assays for the measurement of DENV
neutralization and a comparison of the flow cytometry-based
assays to the classical PRNT.
A 96-well-format, flow cytometry-based DENV neutraliza-
tion assay was developed by using Vero (clone 81) cells or
U937 cells expressing dendritic cell-specific intercellular adhe-
sion molecule 3-grabbing nonintegrin (DC-SIGN), a known
attachment factor for DENV (15, 18). The DC-SIGN-trans-
fected U937 cells were kindly provided by Thomas Morrison
and Mark Heise (University of North Carolina School of Med-
icine). The DENVs used in this study were the reference
strains, designated DENV1 WestPac-74, DENV2 S-16803,
DENV3 CH-53489, and DENV4 TVP-360 (provided by Rob-
ert Putnak from the Walter Reed Army Institute of Research,
Silver Spring, MD). A reference panel of human monovalent
sera with neutralizing antibodies to DENV1 through DENV4
and a polyvalent serum with neutralizing antibodies to all four
DENV serotypes was assembled by the World Health Organi-
zation (WHO) and was provided to us by Morag Ferguson of
the National Institute for Biological Standards and Control in
the United Kingdom.
The flow cytometry-based neutralization assays were per-
formed in triplicate in 96-well cell culture plates with flat-
bottom wells. Each well contained 5  104 Vero cells or DC-
SIGN-expressing U937 cells. The amount of virus used in the
assay infected between 7 and 15% of the cells. This amount of
virus was used because a direct positive correlation was ob-
served between the amount of virus added and the number of
infected cells when between 1 and 30% of the cells were in-
fected (data not shown). With greater than 30% infection, the
number of infected cells did not increase in proportion to
the amount of virus added, most likely because the cells be-
come limiting in the infection assay or because not all cells are
equally susceptible to infection. Human immune sera were
serially diluted in fourfold steps (1:20 to 1:20,480), and the
virus was preincubated with the sera in a final volume of 100 l
for 1 h at 37°C. The cells were washed, and 100 l of the virus
and serum mixture was added to the cells for 1 h at 37°C. Next,
the wells were filled with cell culture medium to a total volume
of 250 l, and the plates were incubated for 24 to 48 h at 37°C
in 5% CO2. The cells were prepared for flow cytometry analysis
by washing them in phosphate-buffered saline, treating them
with trypsin to remove adherent cells (Vero cells only), and
transferring them to 96-well plates with round-bottom wells.
The cells were fixed and permeabilized by using a Cytofix/
Cytoperm kit (BD-PharMingen, San Diego, CA) and stained
with fluorescein isothiocyanate-conjugated monoclonal anti-
body 4G2, a monoclonal antibody that recognizes the flavivirus
E protein, as described previously (9). The cells were analyzed
with a FACScan flow cytometer (Becton Dickinson, San
Diego, CA). The serum dilution that neutralized 50% of the
viruses was calculated by nonlinear, dose-response regression
analysis with Prism 4.0 software (GraphPad Software, Inc., San
Diego, CA).
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The Vero cell-based flow cytometry neutralization assay was
evaluated by using WHO reference DENV immune sera spe-
cific for DENV3 (WHO anti-DENV3) and DENV4 (WHO
anti-DENV4). Serial dilutions of the antisera were used in
several independent neutralization experiments with all four
serotypes of DENV. With the WHO anti-DENV3 immune
serum sample, we obtained a mean 50% neutralization titer of
338 for DENV3 and mean 50% neutralization titers of 28, 43,
and 26 for DENV1, DENV2, and DENV4, respectively (Fig.
1A). Similarly, for the WHO anti-DENV4 immune serum sam-
ple we obtained a mean 50% neutralization titer of 440 for
DENV4 and mean 50% neutralization titers of 56, 35, and 46
for DENV1, DENV2, and DENV3, respectively (Fig. 1A).
Thus, the flow cytometry-based neutralization assay with Vero
cells gave the predicted results with these reference serum
samples.
For accurate measurement of virus neutralization, the anti-
body must be present in excess over the amount of virus in the
assay (2, 7, 16). When flow cytometry-based neutralization
assays were done with all four serotypes of DENV by using
twofold more virus than the amount used in the standard assay,
the 50% neutralization titer remained constant, indicating that
antibody was in excess when the assay was performed with our
reference immune sera (data not shown).
As human hematopoietic cells are the main target of DENV
infection, flow cytometry-based neutralization assays were per-
formed with a human monocytic cell line (U937 cells) stably
transfected with DC-SIGN, an attachment factor for DENV
(12, 15). When the percentage of U937 cells infected in the
presence of DC-SIGN was divided by the percentage of control
cells (U937 without DC-SIGN) that were infected, the DC-
SIGN-expressing cells were found to be 10-fold or more sus-
ceptible to infection with all four serotypes of DENV (Fig. 2
and data not shown). Initially, the DC-SIGN-expressing U937
cells were evaluated by using the WHO anti-DENV3 and anti-
DENV4 immune sera (Fig. 1B). With the WHO anti-DENV3
immune serum sample, we obtained a mean 50% neutraliza-
tion titer of 314 for DENV3 and mean 50% neutralization
titers of 37, 91, and 65 for DENV1, DENV2, and DENV4,
respectively (Fig. 1B). Similarly, for the WHO anti-DENV4
immune serum sample we obtained a 50% neutralization titer
of 166 for DENV4 and mean 50% neutralization titers of 20,
28, and 30 for DENV1, DENV2, and DENV3, respectively
(Fig. 1B). Thus, the flow cytometry-based neutralization assays
with Vero cells (Fig. 1A) and DC-SIGN-expressing U937 cells
(Fig. 1B) gave comparable results, indicating that the DENV
neutralization properties of these reference sera were not af-
fected by the use of human or nonhuman cells in the assay.
PRNT is the most widely used and accepted assay for the
measurement of DENV neutralization. The WHO anti-
FIG. 1. Comparison of flow cytometry and plaque-based DENV neutralization assays. WHO reference dengue immune sera with monospecific
immunity to DENV3 or DENV4 were analyzed by the flow cytometry-based neutralization assay with Vero cells (A) and U937 cells expressing
DC-SIGN (B) and by PRNT (C). Each serum sample was tested in duplicate or triplicate against the four serotypes in three independent
experiments. Dark circles, individual 50% neutralization titer measurements; horizontal lines, the mean titer for each group.
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DENV3 and anti-DENV4 immune sera were characterized by
using Vero-81 cells and PRNT, as described previously (3).
With the WHO anti-DENV3 immune serum sample, we ob-
tained a mean 50% neutralization titer of 310 for DENV3 and
mean 50% neutralization titers of 27, 30, and 20 for DENV1,
DENV2, and DENV4, respectively (Fig. 1C). Similarly, for the
WHO anti-DENV4 immune serum sample we obtained a
mean 50% neutralization titer of 505 for DENV4 and mean
50% neutralization titers of 20 for DENV1, DENV2, and
DENV3 (Fig. 1C). Thus, similar neutralization patterns were
observed for WHO anti-DENV3 and anti-DENV4 immune
sera when they were tested by PRNT and the flow cytometry-
based neutralization assays (Fig. 1).
We next tested a variety of monotypic immune sera that
recognized each of the four serotypes and also heterotypic
immune sera from people exposed to secondary DENV infec-
tions to further compare the assays (Table 1). The sera tested
consisted of monotypic WHO reference sera against each of
the four serotypes (WHO anti-DENV1, anti-DENV2, anti-
DENV3, and anti-DENV4 immune sera) and a heterotypic
serum sample that cross-neutralized all four serotypes (WHO
anti-DENV1234 immune serum). The sera also included two
convalescent-phase samples from the University of North
Carolina serum collection. Serum sample A was a convales-
cent-phase sample from a traveler who was infected with
DENV2 (confirmed by virus isolation) approximately 9 years
before this sample was collected. Serum sample B was from a
traveler who was infected with DENV3 (confirmed by virus
isolation) 3 weeks before the sample was collected. For five of
the six serum samples from individuals with primary DENV
infections (WHO anti-DENV1, anti-DENV2, anti-DENV3,
and anti-DENV4 immune sera and serum sample A), the 50%
neutralization titers for the plaque and flow cytometry-based
assays were similar, in that all three assays gave the highest
titers for the homologous virus (Table 1). The exception was
serum sample B, which cross-neutralized all four serotypes.
Serum sample B was a 3-week convalescent-phase specimen,
and people exposed to primary DENV infections have neutral-
izing, cross-reactive antibody for several months after the ini-
TABLE 1. Comparison of flow cytometry- and plaque-based
neutralization assays with reference monotypic and
heterotypic dengue immune sera
Immune serum and
serotype










DENV1 125 75 168
DENV2 20 22 41
DENV3 20 20 20
DENV4 20 20 20
WHO anti-DENV2
DENV1 20 20 20
DENV2 104 157 199
DENV3 20 20 20
DENV4 20 20 20
WHO anti-DENV3
DENV1 27 28 37
DENV2 30 43 91
DENV3 310 338 314
DENV4 20 29 65
WHO anti-DENV4
DENV1 20 56 20
DENV2 20 35 28
DENV3 20 46 30
DENV4 503 440 166
WHO anti-DENV1234
DENV1 413 NDb 1,280
DENV2 663 ND 1,280
DENV3 518 ND 1,280
DENV4 117 ND 1,280
Serum sample Ac
DENV1 78 58 25
DENV2 1,203 651 371
DENV3 39 20 35
DENV4 58 20 44
Serum sample Bd
DENV1 371 5,120 1,280
DENV2 1,280 996 1,145
DENV3 1,280 5,120 1,280
DENV4 1,280 3,529 209
a The values in each cell are the mean 50% neutralization titers determined
from two to three independent experiments. With monotypic dengue immune
sera, the highest titer for each assay is indicated in boldface.
b ND, not determined.
c Serum A is a convalescent-phase sample collected 9 years after a primary
DENV2 infection.
d Serum B is a convalescent-phase sample collected 3 weeks after a primary
DENV3 infection.
FIG. 2. U937 human monocytic cells expressing DC-SIGN are highly
susceptible to DENV infection. U937 cells (A) and DC-SIGN-expressing
U937 cells (B) were inoculated with DENV3 at a multiplicity of infection
of 0.1. Twenty-four hours after infection, the cells were fixed, stained for
viral antigen with monoclonal antibody 4G2, and analyzed by flow cytom-
etry. The flow cytometry histograms are representative of those from
three independent experiments. FSC, forward scatter.
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tial infection. The convalescent-phase serum sample from an
individual exposed to a secondary DENV infection (WHO
anti-DENV1234 immune serum) cross-neutralized all four se-
rotypes when it was tested by the three different assays. Al-
though there were differences in the mean absolute neutral-
ization titers for each assay, this variability was no greater than
the intra-assay variability typically seen for plaque and flow-
based DENV neutralization assays.
It appears that DENV neutralization is primarily dependent on
virus-antibody interactions and not on the cell types used in these
assays or the method used to detect infected cells. Our results are
in agreement with those of a similar study recently conducted by
Martin and colleagues who compared a flow cytometry-based
assay using Raji cells transfected with DC-SIGN to PRNT (14).
Using monoclonal antibodies and DENV immune sera, those
investigators observed qualitatively and quantitatively similar neu-
tralization titers when the flow cytometry-based and plaque-based
assays were compared. We recommend that the flow cytometry-
based assays replace the DENV PRNT. The flow assays are rapid
and suitable for the screening of large panels of sera by using the
96-well plate format described here. The flow cytometry-based
assay can also be performed with human cell lines and even
primary human cells. Finally, many strains of DENV, including
low-passage clinical isolates, can be used in the flow cytometry-
based neutralization test, as the virus is not required to form
plaques.
The flow cytometry-based assays also have some limitations.
The intra-assay variability was high especially when the same
samples were tested on different days (Fig. 1A and B). In this
respect, the flow cytometry-based assays were not very differ-
ent from PRNT, which also has high variability (Fig. 1C).
Experiments are currently being done to further improve the
reproducibility of the flow cytometry-based neutralization as-
says. It is also more difficult to achieve conditions of antibody
excess with the flow cytometry-based assay than with the
plaque assay. In a typical PRNT setup, less than a 100 infec-
tious units of virus are incubated with antibody per well. The
flow cytometry-based assay requires 1,000 to 10,000 infectious
units per well. Even with these high concentrations of virus, it
was easy to achieve antibody excess with human DENV im-
mune sera. However, with low concentrations of specific anti-
body such as those found in hybridoma supernatants, one
might have to refine the assay to ensure antibody excess. As
flow cytometry requires expensive equipment that is difficult to
maintain, the flow cytometry-based neutralization assay can be
performed only in selected laboratories.
In conclusion, flow cytometry-based neutralization assays
offer significant advantages over PRNT for measuring antibody
neutralization of DENV. As dengue vaccines are already being
tested in clinical trials, there is a need for assays that can
rapidly screen large numbers of serum samples for their neu-
tralization of contemporary strains of DENV. The 96-well-
format flow cytometry-based neutralization assays described
here will greatly facilitate the characterization of human anti-
body responses following vaccination and natural infection.
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